How Strategic Protocol Optimization Can Maximize Success for Biotechs
How Strategic Protocol Optimization Can Maximize Success for Biotechs
Sponsored by:
Sponsored by:
More from R&D
• By
Buy boosts the French major's immunology pipeline.
• By
Expert panel including Ashok Venkitaraman, Director of the Cancer Science Institute of Singapore, discusses public health challenges and innovations to help address these. Long-acting drugs, intercepting cancer early and “design thinking” by ophthalmologists in India were among the talking points.
• By
AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.
• By
In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.
More from Scrip
In partnership with
Insights from Novotech on Evolving Trends Impacting Global Clinical Development
Sponsored by:
Delve into the challenges facing the NHS, from rising medicine costs to supply shortages, and how generics and branded generics can provide solutions for a more sustainable healthcare system
Sponsored by:
Access key stats from biotechs on the latest trends impacting oncology R&D, including therapeutic pipelines and clinical trial challenges, AI/ML, and a future outlook on innovation.
Sponsored by:
Gain exclusive insights into the biggest challenges biotechs face in oncology and uncover the latest opportunities to accelerate drug development.